Sarcoidosis: A Great Masquerader-Case Report
Journal Title: Journal of Medical Science And clinical Research - Year 2017, Vol 5, Issue 4
Abstract
Sarcoidosis is systemic disorder of unknown origin characterized by granulomatous inflammation in different organs , most frequently in lungs and affects people of all racial and ethnic groups. Here we present a case of sarcoidosis with respiratory symptoms and an unusual site of subcutaneous nodule. A high index of clinical suspicion led to the correct diagnosis in this atypical presentation
Authors and Affiliations
Sandra Mosses
Acute Rheumatic Fever with Erythema Marginatum-Case Report
Acute rheumatic fever (ARF) is a multisystem disease resulting from an autoimmune reaction to infection with group A streptococcus. Carditis (clinical/subclinical), Arthritis (polyarthritis, mono arthritis, arthralgia),...
Meteroic Determination of Immunological Infertile Males
Background: The inability to conceive within 1 year of unprotected intercourse is estimated to affect upto one in five couples of reproductive age and poses a significant health problem. Presence of antisperm antibodies...
Clinical Analysis of Community Acquired Pneumonia and Hospitalization Outcome
Background: Community acquired pneumonia is one of the major health problem in India. Early diagnosis of patients with CAP and appropriate treatment are important features with impact on overall mortality. Aims and Objec...
Profile of Nodal Tuberculosis at a Tertiary Care Centre, Gwalior, India
Lymphadenitis is the most common extra pulmonary manifestation of tuberculosis. Tuberculous lymphadenitis is considered to be the local manifestation of the systemic disease. A high index of suspicion is needed for the d...
Pathological Patterns and Complete Response Rates after Neoadjuvant Chemotherapy and Chemoradiation in Locally Advanced Breast Cancer- an audit of 104 Patients
Introduction: Locally advanced breast cancer (LABC) is a disease with relatively poor prognosis. The incidence of LABC is high in India constituting about 30-35% of all cases. Neoadjuvant chemotherapy is the standard of...